enVVeno Medical (NVNO) Stock Price, News & Analysis

Company Overview

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Key Stats

• Today's Range: $3.43 to $3.70
• 50-Day Range: $2.49 to $3.61
• 52-Week Range: $2.45 to $6.97
• Volume: 62,986 shs
• Average Volume: 125,955 shs
• Market Capitalization: $64.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

enVVeno Medical Stock Analysis - MarketRank™

enVVeno Medical scored higher than 28% of companies evaluated by MarketBeat, and ranked 737th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for enVVeno Medical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for enVVeno Medical are expected to grow in the coming year, from ($1.30) to ($1.19) per share.

Price to Book Value per Share Ratio

enVVeno Medical has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.45% of the float of enVVeno Medical has been sold short.

Short Interest Ratio / Days to Cover

enVVeno Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enVVeno Medical has recently decreased by 9.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enVVeno Medical does not currently pay a dividend.

Dividend Growth

enVVeno Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.45% of the float of enVVeno Medical has been sold short.

Short Interest Ratio / Days to Cover

enVVeno Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enVVeno Medical has recently decreased by 9.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for NVNO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added enVVeno Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, enVVeno Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,289.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 34.71% of the stock of enVVeno Medical is held by institutions.

NVNO Stock Analysis - Frequently Asked Questions

How have NVNO shares performed this year?

enVVeno Medical's stock was trading at $3.02 on January 1st, 2025. Since then, NVNO shares have increased by 15.6% and is now trading at $3.49.
View the best growth stocks for 2025 here.

How were enVVeno Medical's earnings last quarter?

enVVeno Medical Corporation (NASDAQ:NVNO) posted its quarterly earnings results on Thursday, October, 31st. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.02.

Who are enVVeno Medical's major shareholders?

Top institutional investors of enVVeno Medical include Westside Investment Management Inc. (1.17%) and Fermata Advisors LLC (0.20%). Insiders that own company stock include Robert Andrew Berman, Francis Duhay, Matthew Jenusaitis, Robert Gray, Sanjay Shrivastava and Hamed Alavi.
View institutional ownership trends.

How do I buy shares of enVVeno Medical?

Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of enVVeno Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that enVVeno Medical investors own include Bionano Genomics (BNGO), VBI Vaccines (VBIV), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Amarin (AMRN), Coherus BioSciences (CHRS) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 1/22/2025
• Next Earnings (Estimated): 2/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NVNO
• CUSIP: N/A
• CIK: 1661053
• Web: www.hancockjaffe.com
• Phone: (949) 261-2900
• Fax: 949-261-2992
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,520,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.72%
• Return on Assets: -45.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.01
• Quick Ratio: 22.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.47 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 17,540,000
• Free Float: 14,730,000
• Market Cap: $61.21 million
• Optionable: Optionable
• Beta: 1.21